METROPOLIS

Metropolis Healthcare Ltd.
Registered Office: 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Rd, Worli, Mumbai - 400030, Maharashtra, India.
Corporate Office & Global Reference Laboratory: 4th Floor, Commercial Bldg-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. CIN: L73100MH2000PLC192798.

Ref: MHL/Sec&Legal/2026-27/46 **September 07, 2026**

To,

BSE Limited
Scrip Code: 542650

National Stock Exchange of India Limited
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby inform that the Board of Directors of Metropolis Quality Solutions Private Limited ("MQSPL"), a subsidiary of Metropolis Healthcare Limited ("the Company/MHL"), has today i.e. on Monday, September 07, 2026, approved and entered into:

1. the Share Subscription Agreement with Medsource Ozone Biomedicals Private Limited ("Medsource") and Dr. Puneet Kumar Nigam; and
2. the Shareholder's Agreement ("SHA") with Medsource, MHL and Dr. Puneet Kumar Nigam.

The details as required under the SEBI Listing Regulations are provided in '**Annexure A**' with this intimation.

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh Chandrashekhar Kulkarni

Digitally signed by Kamlesh Chandrashekhar Kulkarni
DN: c=IN, st=Maharashtra, 2.5.4.20=7b2c373c96d15b9bcfca30002f2fbd0e3a8a7775221bd4075c136f7c37ee6541, postalCode=422004, street=SO Chandrashekhar Kulkarni Plot No47 Vrundavan Nagar Dindori Road Near Gajanan Maharaj Mandir Mhasrul Nashik, pseudonym=ce57b9d646ce4631a4e68e0e138a62c3, title=1552, serialNumber=2d68a0037beac42820279c8effc9ae2073aa3f9ef35e80715cbcb9b2acfdcc68, o=Personal, cn=Kamlesh Chandrashekhar Kulkarni
Date: 2026.09.07 18:37:37 +05'30'

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: a/a

Annexure A

(Pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026)

Particulars	**Details**
Details and reasons for restructuring	Metropolis Quality Solutions Private Limited ("MQSPL"), a subsidiary of Metropolis Healthcare Limited ("the Company/MHL"), has approved and entered into: (a) the Share Subscription Agreement with Medsource Ozone Biomedicals Private Limited ("Medsource") and Dr. Puneet Kumar Nigam; and (b) the Shareholder's Agreement ("SHA") with Medsource, MHL and Dr. Puneet Kumar Nigam. Reason for Restructuring: The restructuring is intended to consolidate and streamline the External Quality Assessment Services Business under MQSPL, by bringing together the operational leadership, clinical / diagnostic backing, R&D, and product development capabilities required to scale the business.
Quantitative/qualitative effect of restructuring	Medsource and Dr. Puneet will invest approximately INR 1.10 crore and INR 16 lakh, respectively, in MQSPL. MHL and Medsource shall have the right to nominate Directors on the Board of MQSPL, subject to the terms of the SHA. The protective/reserved matters, along with the clearly defined roles, responsibilities, rights and obligations of each Party, shall be as set out in the SHA. Presently, MQSPL is a wholly owned subsidiary of MHL. Upon consummation of the Transaction and subject to fulfilment of the applicable terms and conditions governing the conversion, in tranches over a period of 5 (five) years, of the 10,000 Optionally Convertible Redeemable Preference Shares issued to Dr. Puneet Kumar Nigam, the shareholding structure of MQSPL, on a fully diluted basis, shall be as follows: MHL – 54.90%; Medsource – 30.60%; and Dr. Puneet – 14.50%.
Details of benefit, if any, to the promoter/ promoter group/group companies from such proposed restructuring	Not Applicable.
Brief details of change in shareholding pattern (if any) of all entities	Change in shareholding pattern of MQSPL: As stated above. There will be no change in the shareholding pattern of MHL, pursuant to the proposed transaction.